- Home
- CMPS vs LAB Comparison
CMPS vs LAB Comparison
Compare CMPS & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- LAB
- Stock Information
- Founded
- CMPS 2020
- LAB 1999
- Country
- CMPS United Kingdom
- LAB United States
- Employees
- CMPS 166
- LAB N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- CMPS Health Care
- LAB Industrials
- Exchange
- CMPS Nasdaq
- LAB Nasdaq
- Market Cap
- CMPS 502.7M
- LAB 473.2M
- IPO Year
- CMPS 2020
- LAB 2011
- Fundamental
- Price
- CMPS $5.20
- LAB $1.29
- Analyst Decision
- CMPS Strong Buy
- LAB Buy
- Analyst Count
- CMPS 7
- LAB 2
- Target Price
- CMPS $17.00
- LAB $2.50
- AVG Volume (30 Days)
- CMPS 1.8M
- LAB 1.2M
- Earning Date
- CMPS 10-30-2025
- LAB 10-29-2025
- Dividend Yield
- CMPS N/A
- LAB N/A
- EPS Growth
- CMPS N/A
- LAB N/A
- EPS
- CMPS N/A
- LAB N/A
- Revenue
- CMPS N/A
- LAB $172,271,000.00
- Revenue This Year
- CMPS N/A
- LAB N/A
- Revenue Next Year
- CMPS N/A
- LAB N/A
- P/E Ratio
- CMPS N/A
- LAB N/A
- Revenue Growth
- CMPS N/A
- LAB 76.33
- 52 Week Low
- CMPS $2.25
- LAB $0.92
- 52 Week High
- CMPS $7.53
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- CMPS 63.09
- LAB 50.42
- Support Level
- CMPS $5.01
- LAB $1.20
- Resistance Level
- CMPS $5.33
- LAB $1.41
- Average True Range (ATR)
- CMPS 0.32
- LAB 0.07
- MACD
- CMPS 0.04
- LAB 0.00
- Stochastic Oscillator
- CMPS 81.63
- LAB 42.86
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.